BET proteins as targets for anticancer treatment
A Stathis, F Bertoni - Cancer discovery, 2018 - AACR
Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate
gene expression and are involved in cancer pathogenesis. Over the last years, several BET …
gene expression and are involved in cancer pathogenesis. Over the last years, several BET …
Targeting BET bromodomain proteins in cancer: The example of lymphomas
Abstract The Bromo-and Extra-Terminal domain (BET) family proteins act as “readers” of
acetylated histones and they are important transcription regulators. BRD2, BRD3, BRD4 and …
acetylated histones and they are important transcription regulators. BRD2, BRD3, BRD4 and …
Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma
Anaplastic large cell lymphomas (ALCLs) represent a relatively common group of T-cell non-
Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but …
Hodgkin lymphomas (T-NHLs) that are unified by similar pathologic features but …
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Bromodomain and extra-terminal domain (BET) proteins, cyclic adenosine monophosphate
response element-binding protein (CBP), and the E1A-binding protein of p300 (EP300) are …
response element-binding protein (CBP), and the E1A-binding protein of p300 (EP300) are …
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
E Bernasconi, E Gaudio, P Lejeune… - British journal of …, 2017 - Wiley Online Library
The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain
and extra‐terminal proteins, the readers of epigenetic acetylation marks, represents a novel …
and extra‐terminal proteins, the readers of epigenetic acetylation marks, represents a novel …
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy
C Mancarella, M Pasello, S Ventura, A Grilli… - Clinical Cancer …, 2018 - AACR
Purpose: Large-scale sequencing studies have indicated that besides genomic alterations,
the posttranscriptional regulation of gene expression or epigenetic mechanisms largely …
the posttranscriptional regulation of gene expression or epigenetic mechanisms largely …
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms
NC Chen, G Borthakur, N Pemmaraju - Leukemia & lymphoma, 2021 - Taylor & Francis
With improved understanding of the epigenetic alterations underlying cancer development,
numerous novel agents targeting pathways involved in epigenetic modifications and …
numerous novel agents targeting pathways involved in epigenetic modifications and …
[HTML][HTML] IRF4 mediates the oncogenic effects of STAT3 in anaplastic large cell lymphomas
C Bandini, A Pupuleku, E Spaccarotella, E Pellegrino… - Cancers, 2018 - mdpi.com
Systemic anaplastic large cell lymphomas (ALCL) are a category of T-cell non-Hodgkin's
lymphomas which can be divided into anaplastic lymphoma kinase (ALK) positive and ALK …
lymphomas which can be divided into anaplastic lymphoma kinase (ALK) positive and ALK …
[HTML][HTML] BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations
T Ma, Y Chen, ZG Yi, YH Li, J Bai, LJ Li, LS Zhang - Genes & Diseases, 2023 - Elsevier
The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation
and facilitate the recruitment of transcriptional elongation complexes. BET protein is …
and facilitate the recruitment of transcriptional elongation complexes. BET protein is …
[HTML][HTML] The heterogeneous landscape of ALK negative ALCL
Abstract Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous
disease including systemic ALK positive and ALK negative entities. Whereas ALK positive …
disease including systemic ALK positive and ALK negative entities. Whereas ALK positive …